Skip to main content

Common deficiencies found in generic Finished Pharmaceutical Product (FPP) applications submitted for registration to the South African Health Products Regulatory Authority (SAHPRA)



The aim of the study was to investigate the common deficiencies observed in the Finished Pharmaceutical Product (FPP) section of generic product applications submitted to SAHPRA. The study was conducted retrospectively over a 7-year period (2011–2017) for products that were finalised by the Pharmaceutical and Analytical pre-registration Unit.


There were 3148 finalised products in 2011–2017, 667 of which were sterile while 2089 were non-sterile. In order to attain a representative sample for the study, statistical sampling was conducted. Sample size was obtained using the statistical tables found in literature and confirmed by a sample size calculation with a 95% confidence level. The selection of the products was according to the therapeutic category using the multi-stage sampling method called stratified-systematic sampling. This resulted in the selection of 325 applications for non-sterile products and 244 applications for sterile products. Subsequently, all the deficiencies were collected and categorised according to Common Technical Document (CTD) subsections of the FPP section (3.2.P).


A total of 3253 deficiencies were collected from 325 non-sterile applications while 2742 deficiencies were collected from 244 sterile applications. The most common deficiencies in the FPP section for non-sterile products were on the following sections: Specifications (15%), Description and Composition (14%), Description of the Manufacturing Process (13%), Stability Data (7.6%) and the Container Closure System (7.3%). The deficiencies applicable to the sterile products were quantified and the subsection, Validation and/or Evaluation (18%) has the most deficiencies. Comparison of the deficiencies with those reported by other agencies such as the USFDA, EMA, TFDA and WHOPQTm are discussed with similarities outlined.


The overall top five most common deficiencies observed by SAHPRA were extensively discussed for the generic products. The findings provide an overview on the submissions and regulatory considerations for generic applications in South Africa, which is useful for FPP manufacturers in the compilation of their dossiers and will assist in accelerating the registration process.


Pharmaceutical companies use data accumulated during discovery and development stages of a pharmaceutical product in order to register and thus market the medicine. Throughout the development stages, they are required to abide by an array of strict rules and guidelines in order to ensure safety, quality and efficacy of the Finished Pharmaceutical Product (FPP) in humans [1]. Inspection of manufacturing plants and laboratory quality control analysis only do not guarantee product quality and safety [2]. All processes involved in the manufacture of the Active Pharmaceutical Ingredients (APIs) and the FPP need to be controlled [2]. Therefore, assessment of the product dossier prior to its acceptance is paramount [2]. Countries possess their own regulatory authority, which is responsible for enforcing the rules and regulations and issue the guidelines to regulate FPP development process, licensing, registration, manufacturing, marketing, labelling and the product life cycle of the FPP. In this highly regulated environment, regulatory affairs play a critical role as the leading department to provide strategic advice on extremely difficult decisions through the life of the FPP [1]. Even with the strict rules and guidelines, very few pharmaceutical companies submit quality dossiers which do not require any additional amendment or additions at initial review. Dossiers possessing a large number of deficiencies will necessitate more interaction between the authority and the manufacturer during the assessment process, thus increasing the turnaround times for registration of medicines [3]. Subsequently delaying patient access to urgently needed medication.

Over the years, a number of regulatory authorities have witnessed and reported on recurring deficiencies observed from the submitted dossiers. Authorities such as United States Food and Drug Administration (USFDA), European Medicines Agency (EMA) and Taiwan Food and Drug Administration (TFDA) have noted how the publication of common deficiencies has resulted in the submission of improved quality dossiers from pharmaceutical companies. The USFDA published a 4-part series citing the common deficiencies observed from the Abbreviated New Drug Applications (ANDA) on the quality aspects of the dossier. Part 1 of the series, dealt with the deficiencies cited in the API section [4]. Part 2–4 of the series was on common deficiencies observed from the FPP part of the dossier [5,6,7]. The 4-part series was however only qualitative and not quantitative. The TFDA also reported on common deficiencies witnessed in the FPP for applications submitted from June 2011 to the end of May 2012 [8], while the EMA’s study focused on applications finalised during the Committee for Medicinal Products for Human Use (CHMP), during 12 consecutive plenary meetings held between 2007 and 2008 [9]. The World Health Organization Pre-Qualification Team (WHOPQTm) reported on the deficiencies observed in the API and FPP sections for products submitted between April 2007 and December 2010 [3]. A guidance document was also published by the WHOPQTm in 2018 to alert manufacturers of the FPP deficiencies witnessed [10]. The studies conducted were aimed at collecting and analysing the quality review issues, which will serve as a reference and a communication medium for applicants to understand the regulatory requirements in the respective countries, which could be useful for compilation of the dossier and to facilitate the approval process.

South African Health Products Regulatory Authority (SAHPRA) has not implemented this transparency since the inception of the authority in 1965. The registration process by SAHPRA involves a scientific evaluation of the dossier submitted by the applicant in the form of a Common Technical Document (CTD). During this evaluation, a list of recommendations is generated related to the quality, safety and efficacy, which are forwarded to the applicant once discussed at the Pharmaceutical and Analytical (P&A) Committee meetings, to be addressed and resolved prior to approval. The P&A Committee managed to conclude and finalise on the scientific assessments of 3148 applications between 2011 and 2017. With SAHPRA receiving approximately 1200 applications annually, by 2016, a backlog of 7902 applications was accumulated. Within the period 2010–2015 only 3779 application were registered or rejected. From the backlog of applications, 4397 applications had not yet been allocated for evaluation while 3505 were in-process in the pre-registration phase. This shows the urgent need to employ measures such as collecting and analysing the quality review issues, thereby accelerating the approval process by the authority.

In order to identify general trends in the quality deficiencies for SAHPRA, we analysed all deficiencies from products finalised during the P&A Committee meetings over a 7-year period (2011–2017). The 3148 applications finalised during this period were considered a large sample to use for the study therefore a statistical sampling approach was employed to obtain a representative sample.

The manufacturing of the FPP is governed by precise requirements and guidelines such as good manufacturing practises and International Conference of Harmonisation guideline, ICH 3QB [11]. This is to ensure that the medicinal products are fit for their intended use and do not pose risks to the patients as a result of inadequate safety, quality or efficacy [12,13,14]. In the assessment of the medicines for registration by regulatory authorities, deficiencies are frequently observed in the applications, thus a proactive approach is intended in order to promote transparency between SAHPRA and the FPP manufacturers. The investigation undertaken is therefore aimed at identifying common deficiencies in the FPP section of applications submitted to SAHPRA. Publication of these will assist in the submission of quality dossiers which will accelerate the registration process and promote access to medicines for patients.


Overall 3148 applications were finalised in the 7-year period, of which 2089 were non-sterile products while 667 were sterile products. Veterinary (68), Biologicals (86), Medical Devices (5) and New Chemical Entities (NCEs) (233) were also finalised by the P&A Committee in the period as shown in Fig. 1, but was not included as part of this study. The NCEs were not included because they involve a more extensive evaluation, which required the compulsory submission of the restricted part of the Active Pharmaceutical Ingredient Master File (APIMF). As a result, a set of additional recommendations which are not observed in the generic applications is usually communicated to the applicant. Biologicals were not included due to the same reasons as the NCEs, as well as due to differences in the nature and preparation of the APIs used, this will necessitate a separate study as per the work published by the EMA on Biosimilars [15]. Veterinary products were not included since the P&A Committee was only providing support to the Veterinary Unit and each application requires the submission of Clinical trial data assessed by the Veterinary Clinical Committee, therefore it would be out of the scope of the research study. Lastly, Medical Devices were not included since the sample was too small to render the deficiencies as common. One of the main reasons for exclusively conducting a study for generics is that the generic applications constitutes majority of the applications received by SAHPRA annually and the lessons learnt from the generic products can also be employed for non-generic applications.

Fig. 1
figure 1

The distribution and grouping of the finalised products between 2011 and 2017 by the SAHPRA P&A Committee, pre-registration Unit

Given the large size of the submitted applications, a statistical method was applied to yield a representative sample adequate to use for the study. The calculated sample size obtained was 325 for the non-sterile products and 244 for the sterile products using the equations reported by Israel (1992) [16] and Kadam et al. (2010) [17] as Eqs. 1 to 4:

$$n_{0} = \frac{{Z^{2 } pq}}{{e^{2} }},$$
$$n = \frac{n.}{{1 + \frac{n. - 1}{N}}}.$$

The equations consist of the following parameters: z = the confidence level corresponds to a z-score, for a 95% confidence level z is 1.96. p = the degree of variability, q relates to degree of variability above, indicated as 1 − p depending on the variability of the population, e = level of precision which is ± 5% for the selected confidence level of 95%, n0 = sample size, n = adjusted sample size for population sizes that are less than 3000, and N = population size [17, 18].

Calculation for the sterile products is stipulated below with a population of 667. The same was applied for non-sterile products with a population of 2089 where the sample size of 325 was obtained:

$$\begin{aligned} n_{0} & = \frac{{Z^{2 } pq}}{{e^{2} }} \\ & = \frac{{1.96^{2} 0.5^{2} }}{{0.05^{2} }} \\ & = 384.16, \\ \end{aligned}$$
$$\begin{aligned} n & = \frac{n.}{{1 + \frac{n. - 1}{N}}} \\ & \frac{384.16}{{1 + \frac{384.16 - 1}{{667}}}} \\ n \, & = \, 244. \\ \end{aligned}$$

Comparison of the calculated sample size with the table reported by Mohammad [18] for a given population size showed similarity in that the reported value for a population of 650 is 242 with the same confidence interval and level of precision. There are many other tables reported [19,20,21] with sample size ranging between 240 and 255.

A multi-stage sampling method called stratified-systematic sampling was employed. In this method, the entire population is divided into a number of homogeneous groups usually known as “strata” and thereafter units are systematically sampled from each of these stratums [21].

It is pivotal to ensure that the selection is not random and biased. Stratified systematic sampling allows for this as it ensures that all critical variables are considered. Aspects such as the applicant, the dosage form, the API used, the therapeutic category and finalisation time of the drug product were considered as important variables when sampling is conducted. Out of the above five variables, the most critical is the therapeutic category since we are dealing with pharmaceutical products. The best way to categorise the products is through their therapeutic indications, i.e. function and pharmacological classification of the drug.

Regulation 25 of Act 101 classifies and categorise medicines in South Africa as follows:

  • Category A for medicines which are intended for use in humans and which are, without manipulation, ready for administration, including packaged preparations where only a vehicle is added to the effective medicine;

  • Category B for medicines which cannot be administered without further manipulation; and

  • Category C for medicines intended for veterinary use, which are without further manipulation, ready for administration including packaged preparations where only a vehicle is added to the effective medicine [22].

All medicines in the population are category A. This category is subdivided into 34 pharmacological classifications, some of which are subdivided further. Each therapeutic category is considered a stratum. These are grouped into 19 categories as depicted in Table 1. The sample size in each stratum varies according to the relative importance of the stratum in the population, i.e. percentage contribution. For example, if 16% of the population are antiviral agents, then 16% of the sample should contain drug products in that group. From Table 1, each stratum is now treated as a population with a specific sample size. The strata are arranged in terms of therapeutic category of the applications. Thus, the numbers in the first column Table 1 are the number of finalised applications within that therapeutic category for sterile products. For example, there were 138 applications finalised with a pharmacological classification, central nervous system depressants.

Table 1 The different strata (pharmacological classifications) generated for sample selection of sterile products

The kth term serves as a constant value used for systematic sampling and is calculated as illustrated in Eq. 5 with N as the population size and n as the calculated sample size [16]. A systematic sample would select the first element and thereafter the kth term on the list afterwards until the required sample has been selected in the whole population. The interval between the selected elements would then be the population size/calculated sample size [16]. The calculated kth term gave the value 2.7.3 (Eq. 6). This therefore makes the value three the kth term for the systematic sampling, i.e. in all strata. This resulted in the sample size of 245. However, 244 was used in accordance to the calculation using Eq. 2. Similarly, this was conducted for the non-sterile products to select the sample size of 325:

$$n = \frac{N}{{k{\text{th}}}},$$
$$k{\text{th}} = \frac{N}{{n}} = \frac{667}{{244}} = 2.73.$$

The full history of all products finalised in the 7-year period (2011–2017) were collected. The history comprises all communication between the authority and applicants in order to reach finalisation. The documents include the recommendations sent to the applicant and the responses received, as well as the evaluation reports of responses in the form of amendment schedules. These paper documents were obtained from the committee meeting minutes and the registry files where all documents relating to the product are placed. The investigation process involved obtaining the type and extent of the deficiencies raised in the first deficiency letter following the initial evaluation process, thereafter, extracting all the responses and feedback during multiple rounds of communication. During collection of the deficiencies, those with a frequency that was observed as less than five were categorised under “other” in the tables and calculated in the relevant section or subsection. The understanding was that these would not be classified as common due to the low frequency.

The study focuses mainly on the FPP which is presented as Module 3.2.P part of the CTD structure of the dossier as stipulated in Table 2, Module 3.2.P entails eight sections in which five consists of subsections. The 3.2.P sections are applicable for all types of medicines including sterile and non-sterile products.

Table 2 FPP (3.2.P) sections and subsections for classification of observations

The deficiencies obtained were reviewed and the frequency of each listed per section and subsection in 3.2.P together with the percentage frequency of the total deficiencies per section and subsection of the CTD, were calculated as follows:

  • Percentage frequency of deficiency identified per section = (frequency of specific deficiency/total number of deficiencies per section of CTD) × 100.

  • Percentage frequency of deficiency identified per overall 3.2.P = (frequency of specific deficiency/total number of deficiencies per overall 3.2.P section of CTD) × 100.

The deficiencies were collected and illustrated as charts and graphs using Microsoft Office Excel® 2016 (Microsoft Corporation, USA).


Deficiencies from non-sterile products

The 325 applications contained a variety of dosage forms which are: film-coated and uncoated immediate release tablets (48%), immediate release capsules (23%), orodispersible tablets (8.0%), extended release tablets (8.0%), extended release capsules (3.5%), chewable tablets (1.2%), powders for suspensions (5.1%) and other (3.2%). The dosage forms which fall under the “other” category included oral solutions, creams, nasal spray, immediate release granules, gels, ointments, suppositories, lozenges and nose drops. A total of 3253 FPP deficiencies were collected from the 325 deficiency letters. Table 3 shows all deficiencies observed from generic non-sterile products that were finalised in the 2011–2017 period by the P&A pre-registration Unit. Figure 2 shows the distribution of the deficiencies and further highlights the 3.2.P sections in the CTD with the most deficiencies. The sections with the highest deficiencies are Module 3.2.P.3 Manufacture of the FPP, (23%) followed by Module 3.2.P.5 Control of the FPP (21%) and 3.2.P.8 Stability (15%). These three sections are considered the most critical sections in the CTD under Module 3.2.P as observed from reports on common deficiencies by other regulatory authorities while reporting [6,7,8,9,10].

Table 3 List of FPP common deficiencies in the 3.2.P section of the CTD recommended by SAHPRA for non-sterile products finalised by the pre-registration unit between 2011 and 2017
Fig. 2
figure 2

The distribution of all deficiencies found in the 3.2.P sections and subsections for non-sterile applications submitted to SAHPRA. Modules: 3.2.P.1 Description and Composition, 3.2.P.2.2 Final Pharmaceutical Product, 3.2.P.2.3 Manufacturing Process Development, 3.2.P.2.4 Container Closure System, 3.2.P.3.3 Description of the Manufacturing Process, 3.2.P.3.4 Control of Critical Steps and Intermediates, 3.2.P.3.5 Process Validation and/or Evaluation, 3.2.P.4.1 Specifications of IPIs, 3.2.P.4.3 Validation of Analytical Procedures of IPIs, 3.2.P.5.1 Specifications of the FPP, 3.2.P.5.3 Validation of Analytical Procedures of FPP, 3.2.P.5.4 Batch Analysis of the FPP, 3.2.P.5.6 Justification of Specifications, 3.2.P.6 Reference Materials, 3.2.P.7 Container Closure System, 3.2.P.8.1 Stability Summary and Conclusions, 3.2.P.8.2 Post Approval Stability Protocol and Stability Commitment, 3.2.P.8.3 Stability Data

Table 3 specifies all the deficiencies observed in the 3.2.P section of the dossier. The deficiencies were calculated as percentage of the deficiencies in each subsection per overall 3.2.P section. For example, there were 274 deficiencies on the pharmaceutical development section, 3.2.P.2, which is granulated as 3.8% for 3.2.P.2.1 components of the pharmaceutical product, 1.4% for 3.2.P.2.2, final pharmaceutical product, 2.0% for 3.2.P.2.3, manufacturing process development and 1.2% for 3.2.P.2.4 container closure system for each subsection in the table.

The results in Table 3 are depicted as a chart in Fig. 2 to clearly show which subsection exhibits the highest and the lowest number of deficiencies. Subsection 3.2.P.5.1 has the highest deficiency covering 15% (71% of the 3.2.P.5 section). Module 3.2.P.1, Description and Composition of FPP, has the second largest number of deficiencies (14%). Module 3.2.P.3.3, Description of the Manufacturing Process has the third highest percentage of deficiencies (13%) with Module 3.2.P.8.3 on stability data of the FPP at 9.3% (66% of the 3.2.P.8 section).

Deficiencies from sterile products

A similar investigation as for the non-sterile products was conducted for sterile products. The 244 sterile product applications consisted of the following dosage forms: concentrate for injection (35%), powder for injection (17%), lyophilised powder for injection or infusion (42%), ophthalmic solutions (4.8%), irrigation solution (0.8%) and a minority of other comprising the remaining 0.4%. These dosage forms were sterile suspensions and chelating agents. A total of 2742 FPP deficiencies related to sterile products were collected from 244 letters.

The 244 letters were obtained and deficiencies outlined in Table 4. Note that the CTD has different requirements in specific sections depending on the dosage form. For example, the sterilisation method selected for sterile products would need to be clearly indicated and justified in accordance to the decision trees for selection of the sterilisation methods (CPMP/QWP/054/98) [23] under 3.2.P.2.2. This is not a requirement for non-sterile products. There are a number of these sections in the CTD and those deficiencies are listed in Table 4. There are also a number of common sections where the requirements are the same whether a product is sterile or not, for example, 3.2.P.6 Reference Materials, 3.2.P.5.4, Batch Analysis, 3.2.P.5.5 Characterisation of Impurities, etc. Therefore, the deficiencies for sterile products are over and above those listed under Table 3 for non-sterile products depending on their applicability to the dosage form.

Table 4 List of FPP common deficiencies in the 3.2.P section of the CTD recommended by SAHPRA for sterile products finalised by the pre-registration Unit between 2011 and 2017

Figure 3 highlights the most frequently observed deficiencies from the sterile products. It shows that FPP subsections Module 3.2.P.3.5, Process Validation and/or Evaluation (17%), Module 3.2.P.2.2, Development of FPP (13%), Module 3.2.P.8.3, Stability Data (12.6%), Module 3.2.P.3.3, Description of the Manufacturing Process (12.5%) and Module 3.2.P.5.1, Specifications (11%) fall under the top five most common deficiencies requested by SAHPRA for sterile products.

Fig. 3
figure 3

The distribution of deficiencies relating to sterile products. Modules: 3.2.P.1 Description and Composition, 3.2.P.2.2 Final Pharmaceutical Product, 3.2.P.2.3 Manufacturing Process Development, 3.2.P.2.4 Container Closure System, 3.2.P.2.5 Compatibility, 3.2.P.3.3 Description of the Manufacturing Process, 3.2.P.3.4 Control of Critical Steps and Intermediates, 3.2.P.3.5 Process Validation and/or Evaluation, 3.2.P.4.1 Specifications of IPIs, 3.2.P.5.1 Specifications of the FPP, 3.2.P.5.3 Validation of Analytical Procedures of FPP, 3.2.P.5.6 Justification of Specifications, 3.2.P.7 Container Closure System, 3.2.P.8.3 Stability Data, 3.2.R.1 Pharmaceutical and Biological Availability


The most frequent common deficiencies observed by SAHPRA in the submitted non-sterile and sterile products are extensively discussed below as depicted Figs. 2 and 3.

Deficiencies in Module 3.2.P.3., manufacture of the FPP

The highest section reported as per Fig. 2 was Module 3.2.P.3. Further analysis (Fig. 3) reveals that 13% of the overall deficiencies were due to Module 3.2.P.3.3—Description of Manufacturing Process and Process Control, 7.4% on Module 3.2.P.3.4—Control of Critical Steps and Intermediates and 2.2% on Module 3.2.P.3.5—Process Validation and/or Evaluation. Concerning sterile product deficiencies, a similar trend is witnessed where the highest reported section is Module 3.2.P.3, manufacture of the FPP. Module 3.2.P.3.5, Process Validation and/or Evaluation, constitutes 17% of the deficiencies, followed by 12.5% from Module 3.2.P.3.3, Description of the Manufacturing Process and lastly, 2.2% from Module 3.2.P.3.4, Control of Critical Steps and Intermediates.

The common deficiencies observed in the manufacturing process of non-sterile products included: insufficient information being provided on the manufacturing process such as duration of treatment; manufacturing conditions (temperature and humidity); specifications for machine settings; capacity of equipment compression procedure and speed; sieve sizes used; duration of stirring and drying temperatures. These and more are critical parameters that should be included in the process to provide the evaluator with a comprehensive description of the manufacturing process. The second deficiency was on the hold time period not being indicated as well as the bulk containers used for the intermediates and final product before packaging. The proposed holding time is dependent on the shelf life, whereby a holding time exceeding 25% of the shelf life [24] should be supported by accelerated and long-term stability data for approval. There were a large number of deficiencies where applicants did not indicate the proposed period, did not provide a hold time study report in Module 3.2.P.3.5, process validation and/or evaluation and supporting data in 3.2.P.8.3, stability data, if the proposed period exceeds the acceptable conditions as indicated above.

The common deficiencies witnessed from the sterile products in this prevalent section was on subsection, Module 3.2.P.3.5 Process Validation and/or Evaluation. The deficiencies included issues on the validation and outstanding summary report on validation of; the sterilisation method used, media fill procedures, depyrogenation of glass containers and sterilisation for rubber stoppers and autoclaving of production equipment. These are a requirement and should normally be submitted by the manufacturer when the product is considered sterile using aseptic processing or terminal sterilisation. It is imperative that the container used, the excipients, the FPP and container closures be sterile or sterilised for these products, therefore, summary reports on how the validation is conducted is vital. Media fill simulations are also of importance as they assess the performance of an aseptic manufacturing procedure using a sterile microbiological growth medium, in place of the FPP solution, to test whether the aseptic procedures are adequate to prevent contamination during actual FPP production [25,26,27]. The section comprised 54% of these deficiencies.

A common deficiency in the section, 3.2.P.3, Manufacture of the FPP, is the lack of inclusion of environmental classification of areas in the manufacture of sterile products. The classified rooms help the sterile pharmaceutical industry to manufacture products that are free from particulate and microbial contamination [27, 28]. The areas have a controlled contamination level, which is specified regarding the number of particles for every cubic meter for a specified particle size. These restricted areas are constructed with strict humidity, temperature and pressure control conditions to minimise the generation, introduction and retention of particulate matter inside the rooms [28, 29]. The classifications are either A, B, C and D with sterile environments normally using Class A or B or a combination of both. This requirement is therefore very critical in the manufacture of a sterile product and should be specified in the process. These deficiencies comprised 16% of the section.

Deficiencies in Module 3.2.P.5., control of the FPP

The section with the second highest deficiencies is Module 3.2.P.5, control of the FPP, (21%) as depicted in Fig. 2. Figure 3 further shows that subsection 3.2.P.5.1, Specifications, had the most deficiencies in the whole 3.2.P reported for non-sterile products. Missing dissolution profiles and/or unacceptable dissolution limits were observed from nearly all the applications. Multimedia dissolution profile data on the biostudy test product is critical and used as reference data set that is used to support and assign dissolution limits in accordance to the EMA reflection paper [30]. The reports indicate that manufacturers often assign dissolution limits that are wider than the biostudy test product. This leads to back and forth communication between the applicant and the authority. Applicants often justify the widened limits based on the results of the stability results, however, this is not accepted since the acceptance criterion set should be based on the biostudy product. The behaviour should not change during stability as any deviation confirm deterioration of product quality. This is also part of the reason why the proposed dissolution specifications for release and shelf life should not differ as the product quality is expected to remain the same throughout shelf life as per the biostudy test product.

Module 3.2.P.5.1, Specifications, contains a number of deficiencies (58%) involving the request to tighten the proposed specifications based on batch analyses data, stability results and limits as indicated in ICH guidelines. For degradation/related impurities, manufacturers are required to ensure that the proposed specifications are in line with the recognised pharmacopoeia or that the limit is in accordance with ICH guidelines Q3B (R2) [11]. The limit should be below the calculated qualification threshold or reporting threshold. It was also observed that the acceptance criteria set for any other unknown impurities did not conform to ICH requirements. Impurities that are structural alerts for genotoxicity need to be controlled at the Threshold of Toxicological Concern (TTC) of 1.5 mcg/day, as found in the European Medicines Agency (EMA) [31, 32] and draft FDA guidance [33]. However, a higher limit may be proposed based on safety studies demonstrating that the proposed limit does not pose a safety concern. Other limits such as water content, assay, disintegration time are based on the batch analyses and stability results observed. A reasonable proposed limit would need to be justified by supporting data for acceptability if not already indicated in the pharmacopoeia or guidelines.

The most frequent deficiency observed for sterile products in this subsection is the request to include the limit for bacterial endotoxin in the FPP specifications. Endotoxins released from Gram-negative bacteria are the main reason of contamination in pharmaceutical products and as a result of this, an endotoxin test is required to be performed on sterile products especially those which are to be injected in the body so as to avoid bringing adverse effects to human [34].

Deficiencies in Module 3.2.P.8, stability

The section with the third highest deficiencies is Module 3.2.P.8, Stability of the FPP, (15%) for non-sterile products. It comprises Module 3.2.P.8.1 (7.6%), -Stability Summary and Conclusions, Module 3.2.P.8.2 (1.8%) Post-Approval Stability Protocol and Stability Commitment and Module 3.2.P.8.3 (9.3%)—Stability Data. The frequent deficiencies in subsection 3.2.P.8.3, Stability Data, were on the limits proposed on degradation impurities and total impurities being too wide and applicant requested to tighten them in reference to the stability results, this relates to subsection 3.2.P.5.1, Specifications, as discussed above. The other deficiency was on the applicant omitting critical stability indicating parameters such as dissolution, total impurities or degradation impurities in the stability testing. Acceptance of a product cannot be granted if the stability testing does not include these critical parameters which determine the behaviour of the product throughout its shelf life.

There were 12.6% of the additional deficiencies specific to sterile products witnessed in subsection 3.2.P.8.3, Stability Data. The deficiencies were on the request for results of the in-use stability study confirming stability of the product at a specific temperature for a specified amount of time as indicated in the Professional Information (PI). Since the products are sterile, there is a requirement that if the product is not for single use such as ophthalmic solutions, lyophilised powders for infusion, etc., stability results should be conducted to confirm that the product quality is not compromised while in-use. Another list of stability data required involved studies to confirm compatibility of the selected diluent used for infusion solutions, photostability studies to confirm the effect of light on the final product and transportation stability test at specified elevated storage conditions.

Deficiencies in Module 3.2.P.1, description and composition of the FPP

There is 14% of deficiencies attributed to Module 3.2.P.1, Description and Composition of the FPP, from the whole 3.2.P section. The deficiencies in the section comprised requests for the potency adjustment calculation to be included. This equation clearly outlines the quantities required for the API depending on the assay of the API batches used. It also factors the water content present in the API and corrects to provide the acceptable quantity to be used. This should be included as a footnote under the composition table in 3.2.P.1. The other common deficiency in this section was on the indication of the polymorphic form used. The FPP manufacturer has to include the type of polymorphic form used in the batch formula as well as studies conducted to confirm the polymorphic form. They are required to provide the physico-chemical properties of the API in Module 3.2.P.2, pharmaceutical development, which will include polymorphic form investigation, particle size distribution and solubility. It should be noted that these parameters are not critical and may not be controlled by the final product manufacturer if the manufacturing process employs the following techniques which enhance the solubility as a result of the formation of the amorphous form of the product:

  • Complete dissolution of the API in a diluent—results in the formation of an amorphous form [35].

  • Hot melt extrusion which forms a solid dispersion of the API resulting in the formation of an amorphous polymer with enhanced solubility and bioavailability [36, 37].

The most common deficiency witnessed from sterile products in this section is on the request to include the pressure source used for filtration in the batch formula or composition list. The pressure source commonly used is nitrogen gas. It is also imperative that the pressure source used be sterile, this can be indicated in Module 3.2.P.4.

Deficiencies in Module 3.2.P.7, container closure system of the FPP

The most common deficiencies in the section included the request for the following regarding the immediate container closure system:

  • CoAs of the immediate container closure system (CCS),

  • Identification, chemical nature and density of the container closure as well as specifications and the relevant control procedures,

  • Colour, dimensions and thickness of the container closure system,

  • The integrity for the heat seal bond strength (see Table 3).

Manufacturers are required to include the testing parameters used for the container closure system as well as analytical procedure used to do the test. Further description of the CCS is also frequently requested such as colour, dimensions and thickness. This needs to concur with the description in the PI and Patient Information Leaflet (PIL). This section also relates to Module 3.2.P.2.4 where developmental studies on the CCS should be conducted and the most common deficiency is that the manufacturers do not provide or poorly documenting the suitability of the container with the final product. This should include performance studies, suitability, compatibility and safety of the CCS. The common deficiency is frequently cited for sterile products in the section since compatibility studies with all components the final product is in contact with should be provided. For non-sterile products, a frequent response normally refers to the stability data provided in 3.2.P.8.3 or the confirmation that the reference product also uses the identical CCS. SAHPRA accepts these justifications.

Comparison with other authorities

The reported deficiencies listed in Tables 3 and 4 have been compared with those published by other authorities and discussed below.

Comparison of deficiencies, SAHPRA vs USFDA

The USFDA published a four-part series on common deficiencies witnessed in the ANDA applications they received before 2010. Part 2–4 includes the common deficiencies found in the 3.2.P section of the CTD with Part 2 covering Module 3.2.P.1 and 3.2.P.4 on description, composition and excipients [5]. Part 3 covers Module 3.2.P.5 and 3.2.P.8 [6] while Part 4 covers the common deficiencies in Module 3.2.P.2/3 and 3.2.P.7, Manufacture and Container Closure System [7]. A quantitative comparison cannot be made since USFDA did not quantify the frequency of deficiencies. Some of the common deficiencies highlighted in 3.2.P.3 were on the in-process controls and tests (3.2.P.3.4, control of critical steps and intermediates) which is also 37% of deficiencies in the subsection by SAHPRA. Queries on granulation process was also reported to be significantly high and manufacturers were requested to provide a definitive quantitative end-point. A deficiency is included if no control or justification is provided by the applicant and the sole control proposed is a subjective, visual observation. For high shear processes, suitable controls may be related to the change in power consumption with respect to the granulation equipment (e.g., amperage). For fluid bed processes, moisture content can be a suitable control for end-point of the desired granules [7]. There were 5.9% of the deficiencies in the subsection requesting this by SAHPRA. For sterile products, the reported common deficiency was on excess fill volume and studies on extractable volume. A justification should be provided under manufacturing development based on data of multiple containers demonstrating that the intended volume can be extracted. Large overfills exceeding the required limit according to the USP 1151 general chapter [37, 38], should be appropriately justified as this may pose potential safety concerns. There were 9.6% of these deficiencies reported by SAHPRA for the applicable dosage forms. The most prevalent deficiency from Part 3 was on the control of the final product, specifications (3.2.P.5.1) which is also one of the highest common deficiency observed by SAHPRA at 58% in the subsection. The reported deficiencies are confirmed to be similar to those included in this study by SAHPRA.

Comparison of deficiencies, SAHPRA vs TFDA

A report by TDFA was made for applications submitted between June 2011 and May 2012 [8]. Deficiencies in the specification of the final product were the most prevalent in the final quality assessment reports. Issues regarding the specification of the final product were mainly related to the test item, related substances, or degradation products [8]. The second deficiency was for the validation of analytical procedures and mainly related to the validation for related substances/degradation products. The issues were mainly about the inadequate range/linearity and incomplete information about the characteristics (specificity, accuracy, precision, etc.) [8]. These deficiencies comprised 46% of subsection Module 3.2.P.5.3 for SAHPRA submissions. The other deficiency witnessed was regarding the manufacturing process which included inappropriate overages applied, an unjustified change in the manufacturing process, unclarified batch sizes, and others. These are similar to those reported by SAHPRA as seen from Tables 3 and 4 above. The top five deficiencies reported by SAHPRA are very similar to those reported by the TFDA (Table 5).

Table 5 Comparison of the top five common deficiencies from the five regulatory bodies listed below

Comparison of deficiencies, SAHPRA vs EMA

The study by the EMA was conducted on applications finalised by the CHMP, during 12 consecutive plenary meetings held in 2007 and 2008. The concerns raised by the Committee were on control of FPP (32% for 3.2.P.5.1), followed by concerns on the manufacturing (21% for 3.2.P.3), product development (17% for 3.2.P.2) and stability (17% for 3.2.P.8) [9]. This is similarly observed by SAHPRA as shown in Table 5, which compares the frequent deficiencies with what other authorities and organisations reported.

With respect to stability (3.2.P.8), 32% of concerns were regarding the lack of data submitted by the applicant to substantiate the proposed shelf-life of the FPP. For pharmaceutical development (3.2.P.2), 16% of concerns had to do with the results from comparative in vitro studies (for example the dissolution) or comparative in vivo studies (e.g., bioequivalence) requiring further discussion as well as a lack of information on the discriminatory power of dissolution method used [9]. These deficiencies were also observed by SAHPRA in the respective sections. The EMA also published a recent study reporting on common deficiencies witnessed for biosimilar submissions [15] Although these are different to orthodox medicines with respect to the API synthesis in most cases, there is similarity of these products with sterile products since most biosimilars are sterile. There were a number of similar deficiencies reported with those reported by SAHPRA. The deficiencies are; variety of media fill validation issues, validation of depyrogenation of glass vials and hold time validation issues in 3.2.P.3.5 (47% in the section), filter material and filter pore size not included in 3.2.P.3.3, lyophilisation conditions of the cycle used not indicated in 3.2.P.3.3 (28%) and compatibility studies of the FPP with the equipment not indicated in 3.2.P.2.4 (17%) [16]. Table 4 on the additional sterile product deficiencies also highlights these in the respective sections thereby confirming similarity.

Comparison of deficiencies, SAHPRA vs WHOPQTm

The WHOPQTm published FPP deficiencies observed in applications submitted between April 2007 and December 2010. The deficiencies reported were on missing executed and blank manufacturing records (BMRs), inadequate description of equipment, process parameters and end-point determination, inadequate description of sterile processes, unsatisfactory in-process tests and their frequency or acceptability of intermediate product specification, for Module 3.2.P.3 [3]. All the above have also been requested by SAHPRA as observed in Tables 3, 4 and 5. Previously, SAHPRA only requested the BMRs and packaging records when the need arose from the evaluations since they were the principle requirement during inspections. However, this condition was amended in 2020 by SAHPRA and is now a requirement during evaluations. Inadequate or poorly defined end-point for wet granulation process was another common deficiency as well as hold time related deficiencies from the guidance document [10]. These were also observed by SAHPRA and discussed in previous sections.


The main objective of this study was to provide a comprehensive list of common deficiencies encountered by SAHPRA from the submitted 3.2.P section of CTD dossiers. The issues raised stem from product development, production and control of FPPs. The list is aimed at assisting manufacturers and applicants who submit future products to anticipate and avoid common pitfalls in regulatory affairs. Thus, as a result, this study will help pharmaceutical companies and manufacturers in reducing unnecessary and avoidable delays in the registration of these products to the benefit of accelerated access of medicines to patients. Comparisons with other regulatory authorities showed that other international regulatory agencies also observe similar common deficiencies as SAHPRA. This confirms the similarity in the extent of scientific assessments by the authorities, thus ensuring that quality, safe and efficacious medicines is available to patients.

Limitations and future work

The study could not be conducted for applications finalised between 2018–2020 due to the following: the authority transitioned from the Medicine Control Council (MCC) to SAHPRA in 2018. In that time, SAHPRA staff continued to be housed in Civitas building in Pretoria with the National Department of Health employees. From April 2018, the department employees working in the Civitas building embarked on a protest action because of concerns about working conditions in the building. In the medium term, SAHPRA as a section 3A public entity, moved into new premises at the end of 2018. In addition, a backlog project was initiated in 2020, which required SAHPRA evaluators to implement, induct and train new evaluators involved in the project. As a result, information for 2018–2020 is not included in this study due to the disruptions caused by the protesting action, the move to the new premises and the initiation of the backlog project.

Further investigations will be conducted on other sections within the CTD to provide additional assistance in informing manufacturers and research organisations partaking in pharmaceutical development with the intent to obtain approval/registration from regulatory authorities.

Availability of data and materials

Data not available due to privacy and confidentiality restrictions.


  1. Mallik J. 2nd International Conference and Exhibition on Pharmaceut Reg Affairs, 1:4, November 23–24, 2012. ISSN: 2167-7689 Accessed 02 February 2021.

  2. Rago L, Santoso B. Drug regulation: history, present and future. In: van Boxtel CJ, Santoso B, Edwards IR, editors. Drug benefits and risks: international textbook of clinical pharmacology, revised. 2nd ed. Amsterdam: IOS Press; Uppsala: UMC; 2008. p. 65–77.

    Google Scholar 

  3. Stahl M, Worku WZ, Gordon J, Rago L. Deficiencies in generic product dossiers as submitted to the WHO Prequalification of Medicines Programme. J Gener Med. 2012;9(2):63–4.

    Article  Google Scholar 

  4. Srinivasan A, Iser R. FDA perspectives: common deficiencies in abbreviated new drug applications: part 1: drug substance. Pharm Tech. 2010;31(1):50–9.

    Google Scholar 

  5. Srinivasan A, Iser R, Gill S. FDA perspectives: common deficiencies in abbreviated new drug applications: part 2: description composition and excipients. Pharm Tech. 2010;34(8):45–51.

    Google Scholar 

  6. Srinivasan A, Iser R, Gill S. FDA perspectives: common deficiencies in abbreviated new drug applications: part 3: control of the drug product and stability. Pharm Tech. 2011;35(2):58–67.

    Google Scholar 

  7. Srinivasan A, Iser R, Gill S. FDA perspectives: common deficiencies in abbreviated new drug applications: part 4: manufacture and container closure system. Pharm Tech. 2011;35(4):62–8.

    Google Scholar 

  8. Chang L, Gau C. Statistics, quality review issues, and beyond for generic drug applications in Taiwan, therapeutic innovation & regulatory. Science. 2013;47(6):670–7.

    Google Scholar 

  9. Borg JJ, Robert JL, Wade G, et al. Where is industry getting it wrong? A review of quality concerns raised at day 120 by the Committee for Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for chemical entity medicinal products. J Pharm Pharm Sci. 2009;12(2):181–98.

    Article  PubMed  Google Scholar 

  10. World Health Organisation Pre-qualification team (WHOPQTm). Common deficiencies in finished pharmaceutical product (FPP) dossiers, February 27, 2018. Accessed 07 June 2021.

  11. ICH. International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH harmonized tripartite guideline: impurities in new drug substances Q3B (R2), 2006.

  12. Accessed 13 June 2021.

  13. EU Guidelines to Good Manufacturing Practice. Medicinal Products for Human and Veterinary Use, Volume 4, Annex 1, Manufacture of Sterile Medicinal Products, 2008, Available at Accessed June 27, 2021.

  14. PIC/S. Pharmaceutical Inspection Convention Guide to Good Manufacturing Practice for Medicinal Products Annex 1, guide to good manufacturing practice for medicinal products, 2021. Accessed December 01, 2021.

  15. Cilia M, Ruiz S, Richardson P, Salmonson T, Serracino-Inglott A, Wirth F, Borg J. Quality issues identified during the evaluation of biosimilars by the European Medicines Agency’s Committee for Medicinal Products for Human Use. AAPS Pharm Sci Tech. 2018.

    Article  Google Scholar 

  16. Israel GD. Sampling the evidence of extension program impact, Fact sheet PEOD-5, 1992.

  17. Kadam P, Bhalerao S. Sample size calculation. Int J Ayuverda Res. 2010;1(1):55–7.

    Google Scholar 

  18. Mohammad FB. Proceedings of the Regional Conference on Statistical Sciences, 2010:147–162.

  19. Cochran WG. Sampling techniques. 2nd ed. New York: John Wiley and Sons Inc; 1963.

    Google Scholar 

  20. Singh AJ, Masuku MB. Int J Econ Commer Manag. 2014;11(2):1–22.

  21. Israel GD. Determining sample size, fact sheet PEOD-6, October, 1992, revised December 2015.

  22. SAHPRA. Regulations to Act 101, Section 25. MCC. Accessed 01 March 2021.

  23. The European Medicines Agency. Committee for medicinal Products for Human Use (CHMP), Decision trees for selection of the sterilisation methods (CPMP/QWP/054/98), April 5, 2000. [accessed 02/06/2021].

  24. SAHPRA. South African Health Products Regulatory Authority, Stability guideline, Version 7, July 2012.

  25. USFDA Guidance for Industry. Sterile drug products produced by aseptic processing—cGMP. US Food and Drug Administration, 2004.

  26. Manufacture of sterile medicinal products. In: The rules governing medicinal products in the European Union Vol. 4. EU guidelines to good manufacturing practice medicinal products for human and veterinary use. Annex 1, Brussels, 2008.

  27. Guidance for industry. Sterile drug products produced by aseptic processing. Japan, 2005.

  28. World Health Organization (WHO) Good manufacturing practices for sterile pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, (WHO Technical Report Series, No. 902), Annex 6; 2002

  29. WHO good manufacturing practices for sterile pharmaceutical products, WHO Technical Report Series, No. 961, Annex 6, 2011.

  30. EMA. European Medicines Agency, Committee for medicinal Products for Human Use (CHMP), Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action, August 10, 2017.

  31. Accessed 05 June 2021.

  32. EMA. Guideline on the Limits of Genotoxic Impurities, Committee for Medicinal Products for Human Use (CHMP) (Doc. Ref EMEA/CHMP/QWP/251344/2006), Jan. 1, 2007.

  33. USFDA. United States food and drug administration, guidance for industry, genotoxic and carcinogenic impurities in drug substances and products: recommended approaches (Rockville, MD, December 2008).

  34. Spoladore A, Gimenes I, Bachinski R, Negherbon JP, Hartung T, Granjeiro J, Gutemberg GG. Standardized pyrogen testing of medical products with the bacterial endotoxin test (BET) as a substitute for rabbit Pyrogen testing (RPT): a scoping review. Toxicol in Vitro. 2021.

    Article  PubMed  Google Scholar 

  35. Kanikkannan N. Technologies to improve the solubility, dissolution and bioavailability of poorly soluble drugs. J Anal Pharm Res. 2018;7(1):00198.

    Article  Google Scholar 

  36. Gryczke A. Solid dispersions by hot-melt extrusion. Pharm Tech Europe. 2012; 24(9).

  37. USP. Unites States Pharmacopoeia, Pharmaceutical dosage forms, USP 1151.

  38. Accessed 16 June 2021.

Download references


The P&A expert advisory Committee members who served between 2011 and 2017 and P&A pre-registration Unit staff are greatly acknowledged for their tireless efforts and expert guidance in ensuring that patients receive quality medicines in South Africa.


The South African National Department of Health and SAHPRA assisted with the funding of the study.

Author information




LM, ML and JJ were involved in the development of the study design. LM collected and analysed the data. LM and ML co-wrote the first draft of the manuscript. JJ reviewed the manuscript and added suggestions. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jacques Joubert.

Ethics declarations

Ethics approval and consent to participate

This study did not require any specific ethical approval. The study was approved by the University of the Western Cape Senate Research Committee.

Consent for publication

Not applicable.

Competing interests

No conflicts of interest that are directly relevant to the content of this article. The views expressed in this article are the personal views of the authors and may not be used or quoted as being made on behalf of, or reflecting the position of SAHPRA.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Editorial responsibility: Zaheer Babar, University of Huddersfield, UK.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Moeti, L., Litedu, M. & Joubert, J. Common deficiencies found in generic Finished Pharmaceutical Product (FPP) applications submitted for registration to the South African Health Products Regulatory Authority (SAHPRA). J of Pharm Policy and Pract 15, 6 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Finished Pharmaceutical Product (FPP)
  • Common deficiencies
  • South African Health Products Regulatory Authority (SAHPRA)
  • Non-sterile products
  • Sterile products